August 18, 2015 08:30 AM Eastern Daylight Time
NEW YORK--(BUSINESS WIRE)--
Vantage mHealthcare, Inc. (VNTH) (“Vantage Health” or the “Company”) today announced that Nanobeak LLC, its parent company, has engaged China Merchants Bank New York for a private placement of $20 million in equity for the Company exclusively for China.
Headquartered in China, China Merchants Bank Co., Ltd. is a leading commercial bank for corporate/investment banking and personal banking. With total assets of US $764 billion and a ROE of 19% at yearend 2014, China Merchants Bank was awarded the “Best Bank in China” by the Global Finance of the United States in their selection of the “Best Banks in Emerging Markets”. China Merchants Bank is presently the 6th largest bank in China.
Upon closing, this $20 million equity round will be used to fund expanded laboratory facilities in Mountain View, California, recruit additional scientific staff, fund clinical trials and subsequent regulatory approval. The prospective equity partner from China will also help the Company to develop strategic partnerships in China, the largest healthcare market in the world, for distribution and sales of the Nanobeak technology once development is concluded and regulatory approvals have been met.
Mr. Chengyue Jiao, General Manager of China Merchants Bank New York Branch commented, “We are excited to work with a US medical device company dedicated to providing a revolutionary product for early stage cancer detection. With its success, it will benefit patients and consumers in China tremendously, and help to reduce death rates and create social benefits. We are delighted the Company chose to work with China Merchants Bank as its exclusive transaction adviser for China, and to leverage our extensive client relationships there to capture the capital and investment interest to support one of the world’s largest healthcare markets.”
Mr. Joseph Peters, President of Vantage mHealthcare said, “We have been searching for
Instead of just sitting around waiting for FDA ,Cytosorbents is selling in over 30 countries, thanks to Dr. Chan genius , we are going to a new level, and that is up .
Democrats hate people making a good paychecks , as long as this product is eventually sold in the USA and saves lives, I hope they all get a million dollar yearly paychecks.
170 million market cap is very very low for what market Cytosorbents owns , If Cytosorbents doesn't get bought out , we will see a 3 to 5 billion market cap in 3 to 5 years .
Invest in High technology VNTH ,or a plastic non working BLOZF sensor , the choice is yours.
From Life Sciences Report Dated 7/15/2015. Four Small-Cap Medtechs Primed for Outsize Returns: Zacks' Brian Marckx.
BM: CytoSorbents Corp.'s (CTSO:OTCBB) flagship product is called CytoSorb, another blood filtration device. It is a cartridge filled with highly porous, adsorbent polymer beads that connects to an extracorporeal circuit in a standard blood pump machine. These beads filter the blood as it is pumped through, removing excessive and harmful cytokines and other toxic substances. It is designed to treat people who are very sick with critical care illnesses such as sepsis, acute respiratory distress syndrome and acute pancreatitis, all of which can lead to massive organ failure and death.
CytoSorb was shown to be safe and to effectively remove key cytokines in a clinical study in Europe. It has a CE Mark and has been commercialized in Europe for the last few years. Commercialization is following a very structured approach, and is supported by getting the device in front of key opinion leaders and incorporating it in investigator-initiated studies. The company is demonstrating that the product works, that it's efficacious and safe, and this is how CytoSorbents has been able to grow sales and interest.
The company has used a combination of a small in-house sales force and third-party distribution, and has ramped up its geographic footprint fairly rapidly, with distribution now covering more than 30 countries. Distribution partners include some "majors," including Fresenius, the world leader in dialysis, and Biocon, the largest biotechnology company in India. CytoSorbents also recently announced a partnership with an unnamed "top four" medical device company for use of CytoSorb in France for cardiac surgery. Distribution is already substantial and continues to grow.
Revenue grew from about $800,000 in 2013 to $3.1M in 2014. While revenue disappointed somewhat in the first quarter of 2014, it still showed growth. Management attributed the softer-than-expe
AEMD ,would like to know how they would let a company with no sales in sight get on ? CTSO has sales.
BLOZF is the scam stock, no working product, no patents ,they even contacted vantage to licence the narcotics portion of NASA technology and right after Vantage came out with the news they are going after the breath analyzing narcotics industry .